Table 2.
Baseline characteristics of patients between denosumab and zoledronic acid groups
| Characteristics | Denosumab (n = 215) | Zoledronic acid (n = 159) | P value |
|---|---|---|---|
| Male sex, n (%) | 115 (53.5%) | 97 (61.0%) | 0.170 |
| Age (years), median (IQR) | 68 (61–75) | 69 (63–76) | 0.486 |
| Weight (kg), median (IQR) | 56.0 (48.8–62.5) | 54.0 (45.2–62.0) | 0.192 |
| Type of disease, n (%) | |||
| Lung cancer | 113 (53.1%) | 40 (25.2%) | <0.001 |
| Breast cancer | 52 (24.4%) | 15 (9.4%) | |
| Multiple myeloma | 1 (0.5%) | 55 (34.6%) | |
| Prostate cancer | 38 (17.8%) | 16 (10.1%) | |
| Others | 9 (4.2%) | 33 (20.8%) | |
| Comorbid disease, n (%) | |||
| Hypertension | 84 (39.1%) | 72 (45.3%) | 0.244 |
| Diabetes | 40 (18.6%) | 30 (18.9%) | 1.000 |
| Tooth extraction before starting BMAs, n (%) | 58 (27.0%) | 35 (22.0%) | 0.279 |
| Concomitant medication, n (%) | |||
| Oral bisphosphonate | 6 (2.8%) | 7 (4.4%) | 0.409 |
| Antiangiogenic agents a | 47 (21.9%) | 26 (16.4%) | 0.190 |
| Steroid | 105 (48.8%) | 61 (38.4%) | 0.016 |
| Tooth extraction after starting BMAs, n (%) | 13 (6.1%) | 7 (4.4%) | 0.643 |
For continuous values, data are presented as the median (interquartile range (IQR))
MRONJ, medication-related osteonecrosis of the jaw
aIncludes axitinib, bevacizumab, everolimus, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib, and temsirolimus